Autopsy report · NCT03627403

Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

“PI and Sponsor decision. Accrual was low and there was sufficient data to detect a response.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 5 years 10 months before it stopped.
• 17 participants enrolled.
• Results were posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Utah

Sponsor type

University, hospital or other

Conditions

Primary Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis; Post-polycythemia Vera Myelofibrosis

Interventions

Selinexor

Participants

17

Sites

1

Countries

United States

Trials that died the same way

• Value of 3D Modeling in Spine Surgery
  “Sponsor and PI decision” (72% match in meaning)
• Cardiac Shock Wave Treatment in Patients With Reduced Coronary Flow Reserve
  “Sponsor \& PI decision” (68% match in meaning)
• Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts
  “Sponsor decision due to low accrual” (67% match in meaning)
• Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity
  “PI decision due to under accrual.” (65% match in meaning)
• The Effect of a Probiotic Strain on Aspirin-induced GI Damage
  “Decision made by Sponsor” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.